These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 12799972)

  • 1. [Hydromorphone--review of pharmacological properties and therapeutic efficacy with special regard to a controlled release preparation].
    Lindena G; Arnau H; Liefhold J
    Schmerz; 1998 Jul; 12(3):195-204. PubMed ID: 12799972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
    Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
    Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain.
    Hagen NA; Babul N
    Cancer; 1997 Apr; 79(7):1428-37. PubMed ID: 9083166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
    Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
    Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study.
    Ridgway D; Sopata M; Burneckis A; Jespersen L; Andersen C
    J Pain Symptom Manage; 2010 Apr; 39(4):712-20. PubMed ID: 20413058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial.
    Chang AK; Bijur PE; Baccelieri A; Gallagher EJ
    Am J Geriatr Pharmacother; 2009 Feb; 7(1):1-10. PubMed ID: 19281935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials.
    Grosset AB; Roberts MS; Woodson ME; Shi M; Swanton RE; Reder RF; Buckley BJ
    J Pain Symptom Manage; 2005 Jun; 29(6):584-94. PubMed ID: 15963867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Controlled-release hydromorphone in elderly patients with severe pain of different etiologies. Results of an observational study].
    Junker U; Figge V
    MMW Fortschr Med; 2005 Oct; 147 Suppl 3():91-6. PubMed ID: 16261943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
    Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
    Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrathecal hydromorphone for chronic nonmalignant pain: a retrospective study.
    Anderson VC; Cooke B; Burchiel KJ
    Pain Med; 2001 Dec; 2(4):287-97. PubMed ID: 15102233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The side effects of morphine and hydromorphone patient-controlled analgesia.
    Hong D; Flood P; Diaz G
    Anesth Analg; 2008 Oct; 107(4):1384-9. PubMed ID: 18806056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine.
    Bruera E; Pereira J; Watanabe S; Belzile M; Kuehn N; Hanson J
    Cancer; 1996 Aug; 78(4):852-7. PubMed ID: 8756381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OROS® hydromorphone in chronic pain management: when drug delivery technology matches clinical needs.
    Coluzzi F; Mattia C
    Minerva Anestesiol; 2010 Dec; 76(12):1072-84. PubMed ID: 21102402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain.
    Hanna M; Thipphawong J;
    BMC Palliat Care; 2008 Oct; 7():17. PubMed ID: 18976472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral oxycodone: new preparation. No better than oral morphine.
    Prescrire Int; 2003 Jun; 12(65):83-4. PubMed ID: 12825566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of OROS hydromorphone in the management of cancer pain.
    Gardner-Nix J; Mercadante S
    Pain Pract; 2010; 10(1):72-7. PubMed ID: 19863749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacotherapy of chronic, non-tumour related pain. Efficacy, tolerability and patient benefit of an oral osmotic system with hydromorphone].
    Sabatowski R; Giesecke T
    MMW Fortschr Med; 2007 Sep; 149 Suppl 3():119-24. PubMed ID: 17955789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.
    Binsfeld H; Szczepanski L; Waechter S; Richarz U; Sabatowski R
    Pain Pract; 2010; 10(5):404-15. PubMed ID: 20384968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain.
    Hays H; Hagen N; Thirlwell M; Dhaliwal H; Babul N; Harsanyi Z; Darke AC
    Cancer; 1994 Sep; 74(6):1808-16. PubMed ID: 7521784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.